Matrix metalloproteinase-2 enhances platelet deposition on collagen under flow conditions

Summary

Platelets contain and release matrix metalloproteinase-2 (MMP-2) that in turn potentiates platelet aggregation. Platelet deposition on a damaged vascular wall is the first, crucial, step leading to thrombosis. Little is known about the effects of MMP-2 on platelet activation and adhesion under flow conditions. We studied the effect of MMP-2 on shear-dependent platelet activation using the O’Brien filtration system, and on platelet deposition using a parallel-plate perfusion chamber. Preincubation of human whole blood with active MMP-2 (50 ng/ml, i. e. 0.78 nM) shortened filter closure time (from 51.8 ± 3.6 sec to 40 ± 2.7 sec, p< 0.05) and increased retained platelets (from 72.3 ± 2.3 % to 81.1 ± 1.8 %, p< 0.05) in the O’Brien system, an effect prevented by a specific MMP-2 inhibitor. High shear stress induced the release of MMP-2 from platelets, while TIMP-2 levels were not significantly reduced, therefore, the MMP-2/TIMP-2 ratio increased significantly showing enhanced MMP-2 activity. Preincubation of whole blood with active MMP-2 (0.5 to 50 ng/ml, i.e 0.0078 to 0.78 nM) increased dose-dependently human platelet deposition on collagen under high shear-rate flow conditions (3000 sec^-1) (maximum +47.0 ± 11.9 %, p< 0.05, with 50 ng/ml), while pre-incubation with a MMP-2 inhibitor reduced platelet deposition. In real-time microscopy studies, increased deposition of platelets on collagen induced by MMP-2 started 85 sec from the beginning of perfusion, and was abolished by a GPIIb/IIIa antagonist, while MMP-2 had no effect on platelet deposition on fibrinogen or VWF. Confocal microscopy showed that MMP-2 enhances thrombus volume (+20.0 ± 3.0 % vs control) rather than adhesion. In conclusion, we show that MMP-2 potentiates shear-induced platelet activation by enhancing thrombus formation.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Matrix metalloproteinases - platelet adhesion - shear stress - TIMP-2

^* These authors contributed equally to this study.

• References

• 1 Gresele P, Falcinelli E, Momi S. Potentiation and priming of platelet activation: a potential target for antiplatelet therapy. Trends Pharmacol Sci 2008; 29: 352-360.
• 2 Nieswandt B, Pleines I, Bender M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J Thromb Haemost 2011; (Suppl. 01) 92-104.
• 3 Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res 2007; 100: 1673-1685.
• 4 Blair TA, Moore SF, Williams CM. et al. Phosphoinositide 3-kinases p110a and p110β have differential roles in insulin-like growth factor-1-mediated Akt phosphorylation and platelet priming. Arterioscler Thromb Vasc Biol 2014; 34: 1681-1688.
• 5 Lupia E, Bosco O, Mariano F. et al. Elevated thrombopoietin in plasma of burned patients without and with sepsis enhances platelet activation. J Thromb Haemost 2009; 07: 1000-1008.
• 6 Vezza R, Roberti R, Nenci GG. et al. Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. Blood 1993; 82: 2704-2713.
• 7 Wang JS, Cheng LJ. Effect of strenuous, acute exercise on alpha2-adrenergic agonist-potentiated platelet activation. Arterioscler Thromb Vasc Biol 1999; 19: 1559-1565.
• 8 Momi S, Falcinelli E, Giannini S. et al. Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. J Exp Med 2009; 206: 2365-2379.
• 9 Brass LF, Zhu L, Stalker TJ. Novel therapeutic targets at the platelet vascular interface. Arterioscler Thromb Vasc Biol 2008; 28: s43-50.
• 10 Seizer P, May AE. Platelets and matrix metalloproteinases. Thromb Haemost 2013; 110: 903-909.
• 11 Busti C, Falcinelli E, Momi S. et al. Matrix metalloproteinases and peripheral arterial disease. Intern Emerg Med 2010; 05: 13-25.
• 12 Santos-Martinez MJ, Medina C, Gilmer JF. et al. Matrix metalloproteinases in platelet function: coming of age. J Thromb Haemost 2008; 06: 514-516.
• 13 Sawicki G, Salas E, Murat J. et al. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997; 386: 616-619.
• 14 Trivedi V, Boire A, Tchernychev B. et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 2009; 137: 332-343.
• 15 Falcinelli E, Guglielmini G, Torti M. et al. Intraplatelet signalling mechanisms of the priming effect of matrix metalloproteinase-2 on platelet aggregation. J Thromb Haemost 2005; 03: 2526-2535.
• 16 Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metallo-proteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-839.
• 17 Kazes I, Elalamy I, Sraer JD. et al. Platelets release a trimolecular complex components MT-1- MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood 2000; 96: 3064-3069.
• 18 Cecchetti L, Tolley ND, Michetti N. et al. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood 2011; 18: 1903-1911.
• 19 Villeneuve J, Block A, Le Bousse-Kerdilés MC. et al. Tissue inhibitors of matrix metalloproteinases in platelets and megakaryocytes: a novel organisation for these secreted proteins. Exp Hematol 2009; 37: 849-856.
• 20 Falcinelli E, Giannini S, Boschetti E. et al. Platelets release active matrix metallo-proteinase-2 in vivo in humans at a site of vascular injury: lack of inhibition by aspirin. Br J Haematol 2007; 138: 221-230.
• 21 Gresele P, Falcinelli E, Loffredo F. et al. Platelets release matrix metalloprotei-nase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. Eur Heart J 2011; 32: 316-325.
• 22 Lenti M, Falcinelli E, Pompili M. et al. Matrix metalloproteinase-2 of human carotid atherosclerotic plaques promotes platelet activation. Correlation with ischaemic events. Thromb Haemost 2014; 111: 1089-1101.
• 23 Choi WS, Jeon OH, Kim HH. et al. MMP-2 regulates human platelet activation by interacting with integrin alphaIIbbeta3. J Thromb Haemost 2008; 06: 517-523.
• 24 Soslau G, Mason C, Lynch S. et al. Intracellular matrix metalloproteinase-2 (MMP-2) regulates human platelet activation via hydrolysis of talin. Thromb Haemost 2014; 111: 140-153.
• 25 Martinez A, Salas E, Radomski A. et al. Matrix metalloproteinase-2 in platelet adhesion to fibrinogen: interactions with nitric oxide. Sci Monit 2001; 07: 646-651.
• 26 O’Brien JR, Salmon GP. Shear stress activation of platelet glycoprotein IIb-IIIa plus VWF causes aggregation: filter blockage and the long bleeding time in von Willebrand’s disease. Blood 1987; 70: 1354-1361.
• 27 Gresele P, Guglielmini G, De Angelis M. et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003; 41: 1013-1020.
• 28 Gresele P, Marzotti S, Guglielmini G. et al. Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. Diabetes Care 2010; 33: 1262-1268.
• 29 Sixma JJ, de Groot PG, van Zanten H. et al. A new perfusion chamber to detect platelet adhesion using a small volume of blood. Thromb Res 1998; 92: S43-46.
• 30 Momi S, Impagnatiello F, Guzzetta M. et al. NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. Eur J Pharmacol 2007; 570: 115-124.
• 31 Rossiello MR, Momi S, Caracchini R. et al. A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. J Thromb Haemost 2005; 03: 2554-2562.
• 32 Tersteeg C, de Maat S, De Meyer SF. et al. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation 2014; 129: 1320-1331.
• 33 Van Os E, Wu Y-P, Pouwels JG. et al. Thrombopoietin increases platelet adhesion under flow and decreases rolling. Br J Haematol 2003; 121: 482-490.
• 34 Goto S, Tamura N, Ishida H. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 2004; 21 44: 316-323.
• 35 Cozzi MR, Guglielmini G, Battiston M. et al. Visualisation of nitric oxide production by individual platelets during adhesion in flowing blood. Blood 2015; 125: 697-705.
• 36 Mendolicchio GL, Zaloni D, Bacci M. et al. Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood. J Thromb Haemost 2011; 09: 373-382.
• 37 O’Brien JR, Etherington MD, Brant J. et al. Decreased platelet function in aortic valve stenosis: high shear platelet activation then inactivation. Br Heart J 1995; 74: 641-644.
• 38 Menegatti M, Cristalli G, Gallo L. et al. Effect of adenosine derivatives on in vitro thrombus formation induced by shear stress. Haematologica 1999; 84: 721-725.
• 39 Chow TW, Hellums JD, Moake JL. et al. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood 1992; 80: 113-120.
• 40 Brass LF, Shattil SJ. Changes in surface-bound and exchangeable calcium during platelet activation. J Biol Chem 1982; 257: 14000-14005.
• 41 Moake JL, Turner NA, Stathopoulos NA. et al. Shear-induced platelet aggregation can be mediated by VWF released from platelets, as well as by exogenous large or unusually large VWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988; 71: 1366-1374.
• 42 Schulze CJ, Wang W, Suarez-Pinzon WL. et al. Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myo-cardial ischaemia-reperfusion injury. Circulation 2003; 107: 2487-2492.
• 43 Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogen-esis. Int J Biochem Cell Biol 2001; 33: 960-970.
• 44 Kroll MH, Hellums JD, McIntire LV. et al. Platelets and shear stress. Blood 1996; 88: 1525-1541.
• 45 Kulkarni S, Dopheide SM, Yap CL. et al. A revised model of platelet aggregation. J Clin Invest 2000; 105: 783-791.
• 46 Saelman EU, Hese KM, Nieuwenhuis HK. et al. Aggregate formation is more strongly inhibited at high shear rates by dRGDW, a synthetic RGD-containing peptide. Arterioscler Thromb 1993; 13: 1164-1170.
• 47 Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 2008; 28: 403-412.
• 48 Brass LF, Wannemacher KM, Ma P. et al. Regulating thrombus growth and stability to achieve an optimal response to injury. J Thromb Haemost 2011; 09: 66-75.
• 49 Maxwell MJ, Westein E, Nesbitt WS. et al. Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus formation. Blood 2007; 109: 566-576.
• 50 Gear AR, Suttitanamongkol S, Viisoreanu D. et al. Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function. Blood 2001; 97: 937-945.
• 51 Kraemer BF, Schmidt C, Urban B. et al. High shear flow induces migration of adherent human platelets. Platelets 2011; 22: 415-421.